查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1809664

個人化醫療市場（按產品類型、技術、應用和最終用戶分類）—2025-2030 年全球預測

Personalized Medicine Market by Product Type, Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

個人化醫療市場規模預計在2024年達到4,254.8億美元，2025年將成長至4,668.4億美元，複合年成長率為9.92%，到2030年將達到7,506.9億美元。

主要市場統計數據
基準年2024年 4254.8億美元
預計2025年 4668.4億美元
預計2030年 7506.9億美元
複合年成長率（%） 9.92%

個人化醫療的創新正在重新定義患者照護並塑造下一代標靶治療

近年來，個人化醫療已成為醫療創新的前沿，利用基因組學見解和精準診斷技術，根據患者的個別情況量身定做治療方案。分子生物學的突破性進展使研究人員能夠破解疾病的遺傳基礎，為針對特定生物標記的治療方法鋪平了道路。高通量定序和生物資訊學平台的進步促進了從傳統的「一刀切」治療方法轉變為個人化治療的轉變。因此，臨床醫生現在可以識別出最能從特定治療方法中受益的患者，從而提高有效率並最大限度地減少副作用。數位健康工具的整合進一步放大了這種潛力，使得能夠持續監測患者的反應並制定適應性治療方法。

基因定序和數位健康平台的快速發展正在改變全球個人化醫療的格局

過去十年，在基因組定序、數位健康整合和主導分析等技術突破的推動下，個人化醫療領域發生了翻天覆地的變化。全基因定序的成本自誕生以來大幅下降，不僅能洞察患者個體的突變特徵，還能在臨床實務中常規應用伴隨診斷。同時，數位健康平台和穿戴式裝置的普及促進了生物標記的遠端監測，使醫療保健提供者能夠近乎即時地檢測治療反應和病情進展。同時，監管機構，尤其是腫瘤學和罕見疾病領域的監管機構，已經引入了適應性框架，以加快標靶治療的核准，體現了對以患者為中心的治療途徑的更廣泛承諾。

2025 年美國關稅升級將重塑全球個人化醫療市場的供應鏈與成本結構

美國近期推出的2025年關稅調整政策，為個人化醫療價值鏈帶來了新的複雜性。關稅適用於高階試劑、定序設備和專用實驗室耗材等關鍵零件，可能會提高投入成本，並擾亂既定的籌資策略。依賴跨國供應網路的公司現在必須應對成本波動，因為成本波動正在降低利潤率，並迫使其進行策略調整。為此，一些產業相關人員已開始多元化其供應商基礎，探索替代製造地，並將關鍵生產流程在地化，以減輕關稅波動的影響。

產品類型、技術應用和最終用戶的多樣化細分揭示了個人化醫療的多樣化機會

仔細觀察市場細分，可以發現在產品類型、技術、應用和最終用戶類別方面，個人化醫療生態系統呈現截然不同的動態。按產品類型分類，診斷方式涵蓋伴隨診斷、基因檢測、影像學和分子診斷，每種方式在識別生物標記和對患者群體進行分層方面都發揮著關鍵作用。同時，治療方案涵蓋細胞和基因療法、免疫療法、單株抗體和常規藥物，反映了針對潛在疾病機制的廣泛方法。這種二分法凸顯了診斷和治療創新的互補性，即對疾病的準確表徵可以轉化為有針對性的干涉策略。

不同的動力正在推動美洲、歐洲、中東和非洲以及亞太地區的個人化醫療

個人化醫療的區域趨勢反映了美洲、歐洲、中東和非洲地區以及亞太地區不同的重點和發展軌跡。在美洲，對研究基礎設施的強勁投資以及大型生物製藥和診斷公司的入駐，正在推動基因組檢測和標靶治療的快速普及。強調基於價值的醫療服務的政策舉措，以及強大的臨床試驗點網路和報銷途徑，正在進一步加速市場擴張和新治療方法的臨床轉化。

與領先創新者的策略夥伴關係加速個人化醫療生態系統的突破和競爭定位

個人化醫療領域的領先公司正透過對研發的策略投資和加速治療創新的合作聯盟來脫穎而出。一些生物醫學公司已與基因組技術提供者建立獨家合作夥伴關係，共同開發次世代定序方法，而其他公司則投資於專有的生物資訊平台，以增強分子數據的解讀能力。這些策略舉措不僅增強了他們的內部能力，還在競爭格局中創造了差異化定位。

積極主動的策略和戰術性投資可以幫助行業領導者利用新興的個人化醫療趨勢並克服監管障礙

為了充分利用個人化醫療的勢頭並應對不斷變化的監管和商業環境，行業領導者應考慮一些積極主動的策略。首先，投資模組化和靈活的製造能力可以增強企業應對供應鏈中斷和關稅導致的成本波動的能力。在關鍵部件上設立本地生產中心，可以幫助企業確保供應的連續性，同時遵守區域貿易法規。同時，促進研發、監管和商業團隊之間的多學科合作，可以簡化將科學發現轉化為市場化解決方案的過程，以最大限度地縮短患者受益的時間。

嚴格的資料收集、分析和檢驗方法是個人化醫療市場全面調查方法的基礎

此項分析所依據的研究採用了嚴格的多階段方法，以確保準確性和可靠性。首先，我們透過廣泛的公開資訊來源（包括同行評審期刊、監管出版物和行業白皮書）進行了二次研究，以建立對技術趨勢和市場動態的基礎理解。此階段還涉及審查專利資料庫和臨床試驗註冊中心，以確定個人化醫療領域的關鍵創新和開發平臺。

全面個人化醫療創新和策略性適應將推動永續成長並改變全球醫療保健服務模式。

隨著個人化醫療從概念框架邁向臨床實踐，精準診斷、標靶治療和數位健康平台的整合勢必將改變全球患者的治療結果。技術創新、策略性產業合作和自適應監管途徑的整合，正為更有效、更有效率的醫療服務奠定基礎。然而，對於尋求最大限度地發揮個人化介入潛力的相關人員來說，供應鏈不穩定、關稅影響以及區域差異化應用等挑戰仍然是重要的考慮因素。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 將人工智慧驅動的基因組分析整合到醫療網路的常規腫瘤治療決策工作流程中
  • 遠端醫療和數位健康平台的擴展將實現遠距藥物基因組學諮詢和個人化劑量建議
  • 利用單細胞定序技術揭示患者特異性腫瘤異質性模式，以最佳化標靶治療
  • 開發針對個別新抗原譜的 mRNA 疫苗平台，用於下一代個人化癌症免疫治療
  • 新興的多體學資料整合平台，結合蛋白質體學、代謝體學和轉錄組學，實現精準診斷和分層治療
  • 全球不斷發展的法規結構，以支持基於即時生物標記回饋和患者分層的自適應臨床試驗
  • 實施數位雙胞胎技術來模擬患者對客製化治療計畫的複雜生理反應
  • 基於 CRISPR 的基因編輯和遞送系統在罕見單基因疾病個人化治療的進展
  • 整合人工智慧風險預測和生活方式改變建議的消費者基因檢測服務的成長
  • 製藥公司與數位健康Start-Ups建立策略夥伴關係，共同開發個人化藥物輸送和依從性監測設備

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：個人化醫療市場（依產品類型）

  • 診斷
    • 伴隨診斷
    • 基因檢測
    • 影像學診斷
    • 分子診斷
  • 治療藥物
    • 細胞和基因治療
    • 免疫療法
    • 單株抗體
    • 製藥

第9章：個人化醫療市場（依技術）

  • 生物資訊學
  • 數位健康和​​人工智慧
  • 基因組學和蛋白​​質組學
  • 藥物基因組學

第 10 章：個人化醫療市場（按應用）

  • 心臟病學
    • 心律不整
    • 心臟衰竭
  • 內分泌學
  • 感染疾病
    • 細菌
    • 病毒性的
  • 神經病學
    • 神經退化
    • 精神病學
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤

第 11 章：個人化醫療市場（依最終用戶分類）

  • 學術研究機構
  • 診斷實驗室
  • 醫院和診所

12.美洲個人化醫療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 13 章：歐洲、中東和非洲的個人化醫療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

14. 亞太地區個人化醫療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • AMGEN INC
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • Biogen Inc
    • Danaher Corporation
    • Exact Sciences Corporation
    • GE Healthcare Technologies, Inc
    • Guardant Health, Inc.
    • Illumina, Inc.
    • Myriad Genetics, Inc.
    • Novartis AG
    • Pfizer Inc
    • QIAGEN NV
    • Roche Holding AG
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific Inc.
    • PierianDx, Inc.
    • CRISPR Therapeutics AG
    • bluebird bio, Inc.
    • Vertex Pharmaceuticals Incorporated

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-4D00F1312F65

The Personalized Medicine Market was valued at USD 425.48 billion in 2024 and is projected to grow to USD 466.84 billion in 2025, with a CAGR of 9.92%, reaching USD 750.69 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 425.48 billion
Estimated Year [2025] USD 466.84 billion
Forecast Year [2030] USD 750.69 billion
CAGR (%) 9.92%

Innovations in Personalized Medicine Are Redefining Patient Care and Shaping the Next Generation of Targeted Therapeutics

In recent years, personalized medicine has emerged at the forefront of healthcare innovation, harnessing genomic insights and precision diagnostics to tailor treatments to individual patient profiles. Breakthroughs in molecular biology have enabled researchers to decode the genetic underpinnings of disease, paving the way for therapies that target specific biomarkers. This shift from traditional one-size-fits-all approaches to personalized interventions has been catalyzed by advancements in high-throughput sequencing and bioinformatics platforms, which deliver unprecedented resolution into the molecular drivers of pathology. As a result, clinicians can now identify patients who will benefit most from a given therapy, thereby improving efficacy rates and minimizing adverse effects. The integration of digital health tools further amplifies this potential, allowing for continuous monitoring of patient responses and adaptive treatment regimens.

Moreover, the convergence of data analytics and artificial intelligence has accelerated decision-making processes, enabling dynamic patient stratification and real-time adjustments to therapeutic protocols. Through collaborative efforts between research institutions, technology providers, and clinical stakeholders, personalized medicine is transitioning from theoretical promise to clinical reality. This introduction lays the groundwork for a comprehensive exploration of the key drivers, challenges, and emerging trends that define the evolving landscape of individualized healthcare solutions.

Rapid Advances in Genomic Sequencing and Digital Health Platforms Are Transforming the Personalized Medicine Landscape Globally

Over the past decade, the personalized medicine landscape has undergone transformative shifts driven by technological breakthroughs in genomic sequencing, digital health integration, and AI-driven analytics. The cost of whole-genome sequencing has plummeted dramatically since its inception, unlocking previously inaccessible insights into patient-specific mutation profiles and enabling the routine application of companion diagnostics in clinical practice. At the same time, the proliferation of digital health platforms and wearable devices has facilitated remote monitoring of biomarkers, empowering healthcare providers to detect treatment responses and disease progression in near real-time. In parallel, regulatory agencies have introduced adaptive frameworks that accelerate the approval of targeted therapies, particularly in oncology and rare disease domains, reflecting a broader commitment to patient-centric care pathways.

These developments have been complemented by strategic partnerships between biopharmaceutical companies and technology firms, fostering an ecosystem that leverages cross-disciplinary expertise to address complex therapeutic challenges. Collaborative research consortia now convene to standardize genomic data protocols and validate digital health endpoints, further solidifying the infrastructure needed for scalable implementation. In this context, value-based care models are increasingly being adopted, aligning reimbursement with treatment outcomes rather than volumetric service delivery. As personalized medicine continues to mature, these converging forces of innovation, policy evolution, and collaborative synergy are reshaping the healthcare paradigm, setting the stage for unprecedented levels of precision, efficiency, and patient empowerment.

Escalating United States Tariff Policies in 2025 Are Reshaping Supply Chains and Cost Structures in Personalized Medicine Markets Worldwide

Recent policy decisions regarding tariff adjustments in the United States for the year 2025 have introduced a new layer of complexity to the personalized medicine value chain. Tariffs applied to critical components such as high-grade reagents, sequencing equipment, and specialized laboratory consumables have the potential to increase input costs and disrupt established procurement strategies. Companies reliant on cross-border supply networks must now navigate a landscape where cost variances can erode profit margins and necessitate strategic recalibrations. In response, several industry players have begun diversifying their supplier base, seeking alternative manufacturing locations and localizing key production processes to mitigate exposure to tariff volatility.

Beyond direct cost implications, the tariff regime has also influenced collaborative research agreements, as international partners reassess the economic feasibility of joint ventures and technology transfers. Institutions in North America are exploring co-development frameworks with partners in tariff-exempt regions, optimizing for intellectual property protection and tax incentives. Simultaneously, small and medium-sized enterprises face heightened barriers to entry due to increased capital requirements and the need for more robust logistical planning. Despite these challenges, proactive stakeholder engagement with policy-makers and trade associations has emerged as a critical mechanism for advocating for tariff exemptions on life-saving and research-intensive products. Overall, the evolving tariff environment underscores the importance of agile supply chain strategies and cross-sector collaboration in sustaining the momentum of personalized medicine innovation.

Diverse Segmentation Across Product Types Technologies Applications and End Users Reveals Nuanced Opportunities in Personalized Medicine

An in-depth examination of market segmentation reveals distinct dynamics across product type, technology, application, and end user categories that collectively shape the personalized medicine ecosystem. Examining product type, diagnostics modalities span companion diagnostics, genetic testing, imaging diagnostics, and molecular diagnostics, each playing a pivotal role in identifying biomarkers and stratifying patient populations. Therapeutic solutions, on the other hand, encompass cell and gene therapy, immunotherapy, monoclonal antibodies, and conventional pharmaceuticals, reflecting a broad spectrum of approaches to target underlying disease mechanisms. This bifurcation underscores the complementary nature of diagnostic and therapeutic innovation, whereby precise disease characterization informs targeted intervention strategies.

When viewed through the lens of technology platforms, bioinformatics, digital health and artificial intelligence, genomics and proteomics, as well as pharmacogenomics emerge as critical enablers. Bioinformatics tools drive data interpretation, while digital health applications and AI algorithms facilitate real-time patient monitoring and adaptive treatment algorithms. Genomics and proteomics provide the molecular framework for identifying therapeutic targets, and pharmacogenomics informs drug selection based on individual metabolic profiles. These technologies function in concert to enhance the predictive power and personalized precision of clinical decision making.

Application areas further delineate the market's complexity. Cardiology divisions focus on arrhythmia and heart failure, endocrinology leverages hormone profiling, and infectious disease strategies address both bacterial and viral challenges. Neurology initiatives target neurodegenerative disorders and psychiatric conditions, while oncology efforts span hematologic malignancies and solid tumors. Finally, end user ecosystems include academic and research institutes, diagnostic laboratories, and hospitals and clinics, each serving as a crucial node in the translational continuum from discovery science to patient care. This multifaceted segmentation framework highlights the nuanced opportunities and challenges that stakeholders must navigate to drive personalized medicine forward.

Distinct Regional Dynamics Across Americas Europe Middle East Africa and Asia Pacific Are Driving Personalized Medicine Adoption Differently

Regional trends in personalized medicine reflect divergent priorities and developmental trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong investment in research infrastructure and the presence of leading biopharmaceutical and diagnostic companies drive rapid adoption of genomic testing and targeted therapies. Policy initiatives that emphasize value-based care, alongside a robust network of clinical trial sites and reimbursement pathways, further accelerate market expansion and clinical translation of novel therapies.

In contrast, the Europe Middle East and Africa region exhibits a heterogeneous landscape. Western Europe benefits from comprehensive healthcare coverage and regulatory harmonization through centralized agencies, fostering an environment conducive to the uptake of precision diagnostics and innovative treatment modalities. Conversely, emerging markets within the Middle East and Africa are characterized by nascent healthcare infrastructures and reliance on donor-funded programs, which presents both challenges and opportunities for scalable implementation of personalized medicine solutions.

Meanwhile, the Asia-Pacific region stands out for its large patient populations and growing focus on domestic manufacturing capabilities. Governments in key markets are investing in national genomic sequencing initiatives, and collaborative networks have been established to standardize data protocols and facilitate cross-border research. Additionally, partnerships between multinational corporations and local enterprises are enabling technology transfer and capacity building, positioning the region as a critical hub for future personalized medicine developments.

Leading Innovators and Strategic Collaborations Are Accelerating Breakthroughs and Competitive Positioning in the Personalized Medicine Ecosystem

Leading organizations in the personalized medicine arena are distinguishing themselves through strategic investment in research and development, as well as through collaborative alliances that accelerate therapeutic innovation. Several biomedical firms have secured exclusive partnerships with genomic technology providers to co-develop next-generation sequencing assays, while others have invested in proprietary bioinformatics platforms that enhance molecular data interpretation. These strategic maneuvers not only bolster internal capabilities but also create differentiated positioning in a highly competitive landscape.

Moreover, cross-sector collaborations are gaining momentum, with pharmaceutical companies partnering with digital health startups to integrate real-time patient monitoring into clinical trial designs. Such alliances enable more responsive trial protocols, reduce time to actionable insights, and improve patient retention rates. At the same time, emerging biotech companies are pursuing targeted acquisitions to expand their pipeline portfolios and gain access to novel therapeutic platforms, particularly in high-growth areas like cell and gene therapy. Meanwhile, diagnostic firms are forming consortia with academic institutions and contract research organizations to validate biomarkers and regulatory endpoints, reinforcing the evidentiary foundation required for market approval. By leveraging a combination of organic research efforts and external collaborations, these industry players are positioning themselves to lead the transition toward truly personalized healthcare solutions.

Proactive Strategies and Tactical Investments Will Empower Industry Leaders to Capitalize on Emerging Personalized Medicine Trends and Overcome Regulatory Hurdles

To capitalize on the momentum of personalized medicine and navigate the evolving regulatory and commercial landscape, industry leaders should consider several proactive strategies. First, investing in modular and flexible manufacturing capabilities will enhance resilience against supply chain disruptions and tariff-induced cost fluctuations. By adopting localized production hubs for critical components, organizations can ensure continuity of supply while maintaining compliance with regional trade regulations. Concurrently, fostering cross-disciplinary collaboration between R&D, regulatory affairs, and commercial teams will streamline the translation of scientific discoveries into market-ready solutions, minimizing time to patient benefit.

Second, integrating advanced data analytics and artificial intelligence into clinical development and patient engagement workflows will unlock new efficiencies. Machine learning models can predict patient responses and optimize trial design, while digital health platforms facilitate remote monitoring and adherence tracking. These technological investments will not only improve clinical outcomes but also generate real-world evidence that supports value-based reimbursement models.

Third, expanding strategic partnerships with academic centers, specialized contract research organizations, and technology providers will enhance access to cutting-edge expertise and infrastructure. Establishing co-development agreements and consortium-based research programs can spread risk and accelerate proof-of-concept validation. Additionally, engaging with policy-makers and industry associations to advocate for tariff exemptions on essential diagnostic and therapeutic components will help mitigate cost pressures.

Finally, prioritizing patient-centric frameworks-such as incorporating patient-reported outcomes and personalized engagement strategies-will strengthen adoption and long-term market success. By aligning commercialization strategies with patient needs and payer expectations, organizations can build sustainable value propositions that endure in a rapidly shifting healthcare environment.

Rigorous Data Collection Analysis and Validation Methodologies Underpinning the Comprehensive Research Approach in Personalized Medicine Markets

The research underpinning this analysis employs a rigorous multi-stage approach to ensure accuracy and reliability. Initially, secondary research was conducted across a broad spectrum of publicly available sources, including peer-reviewed journals, regulatory agency publications, and industry white papers, to establish a foundational understanding of technological trends and market dynamics. This phase also involved the review of patent databases and clinical trial registries to identify key innovations and developmental pipelines in personalized medicine.

Following this, primary research was executed through structured interviews with subject matter experts, including clinicians, technology providers, and regulatory consultants. These interviews offered qualitative insights into evolving adoption patterns, reimbursement challenges, and strategic priorities. Cross-functional dialogues with industry executives provided additional perspective on investment drivers and partnership opportunities.

Data triangulation techniques were then applied to reconcile findings from both primary and secondary sources. Quantitative data points were validated through multiple independent channels to strengthen confidence in the insights presented. Finally, an iterative validation process was conducted, where preliminary conclusions were reviewed by an external advisory panel to ensure objectivity and relevance. This comprehensive methodology ensures that the analysis reflects the latest evidence and expert perspectives, providing a robust foundation for strategic decision-making in the personalized medicine arena.

Integrated Personalized Medicine Innovations and Strategic Adaptations Are Poised to Drive Sustainable Growth and Transform Healthcare Delivery Models Worldwide

As personalized medicine advances from conceptual frameworks to clinical reality, the integration of precision diagnostics, targeted therapeutics, and digital health platforms is poised to transform patient outcomes globally. The convergence of technological innovation, strategic industry collaborations, and adaptive regulatory pathways has laid the groundwork for more effective and efficient care delivery. However, challenges such as supply chain volatility, tariff impacts, and heterogeneous regional adoption remain critical considerations for stakeholders seeking to maximize the potential of personalized interventions.

By embracing agile manufacturing strategies, fostering co-development partnerships, and leveraging advanced data analytics, organizations can navigate these complexities and achieve competitive differentiation. Simultaneously, prioritizing patient-centric approaches and cultivating evidence generation will bolster payer confidence and facilitate broader market access. As regional ecosystems continue to mature, opportunities for localized innovation and cross-border collaboration will further accelerate progress. Ultimately, the future of healthcare lies in the ability to tailor interventions to individual patient profiles, and those entities that successfully align scientific rigor with operational agility are best positioned to lead this transformative journey.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of AI-driven genomic profiling in routine oncology treatment decision making workflows across healthcare networks
  • 5.2. Expansion of telemedicine and digital health platforms enabling remote pharmacogenomic consultation and personalized dosing recommendations
  • 5.3. Adoption of single-cell sequencing technologies to uncover patient-specific tumor heterogeneity patterns for targeted therapy optimization
  • 5.4. Development of mRNA vaccine platforms tailored to individual neoantigen profiles for next-generation personalized cancer immunotherapy pipelines
  • 5.5. Emergence of multiomics data integration platforms combining proteomics, metabolomics, and transcriptomics for precision diagnostics and treatment stratification
  • 5.6. Regulatory frameworks evolving globally to support adaptive clinical trials driven by real-time biomarker feedback and patient stratification
  • 5.7. Implementation of digital twin technology to simulate complex patient physiological responses to customized therapeutic regimens in silico
  • 5.8. Advancements in CRISPR-based gene editing and delivery systems for personalized treatment of rare monogenic diseases
  • 5.9. Growth of direct-to-consumer genetic testing services integrating AI-powered risk prediction and lifestyle modification recommendations
  • 5.10. Strategic collaborations between pharmaceutical companies and digital health startups to co-develop personalized drug delivery and adherence monitoring devices

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Personalized Medicine Market, by Product Type

  • 8.1. Introduction
  • 8.2. Diagnostics
    • 8.2.1. Companion Diagnostics
    • 8.2.2. Genetic Testing
    • 8.2.3. Imaging Diagnostics
    • 8.2.4. Molecular Diagnostics
  • 8.3. Therapeutics
    • 8.3.1. Cell & Gene Therapy
    • 8.3.2. Immunotherapy
    • 8.3.3. Monoclonal Antibodies
    • 8.3.4. Pharmaceuticals

9. Personalized Medicine Market, by Technology

  • 9.1. Introduction
  • 9.2. Bioinformatics
  • 9.3. Digital Health & AI
  • 9.4. Genomics & Proteomics
  • 9.5. Pharmacogenomics

10. Personalized Medicine Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiology
    • 10.2.1. Arrhythmia
    • 10.2.2. Heart Failure
  • 10.3. Endocrinology
  • 10.4. Infectious Diseases
    • 10.4.1. Bacterial
    • 10.4.2. Viral
  • 10.5. Neurology
    • 10.5.1. Neurodegenerative
    • 10.5.2. Psychiatric
  • 10.6. Oncology
    • 10.6.1. Hematologic Malignancies
    • 10.6.2. Solid Tumors

11. Personalized Medicine Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics

12. Americas Personalized Medicine Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Personalized Medicine Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Personalized Medicine Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Agilent Technologies, Inc.
    • 15.3.3. AMGEN INC
    • 15.3.4. BGI Genomics Co., Ltd.
    • 15.3.5. Bio-Rad Laboratories, Inc.
    • 15.3.6. Bio-Techne Corporation
    • 15.3.7. Biogen Inc
    • 15.3.8. Danaher Corporation
    • 15.3.9. Exact Sciences Corporation
    • 15.3.10. GE Healthcare Technologies, Inc
    • 15.3.11. Guardant Health, Inc.
    • 15.3.12. Illumina, Inc.
    • 15.3.13. Myriad Genetics, Inc.
    • 15.3.14. Novartis AG
    • 15.3.15. Pfizer Inc
    • 15.3.16. QIAGEN N.V.
    • 15.3.17. Roche Holding AG
    • 15.3.18. Siemens Healthcare GmbH
    • 15.3.19. Thermo Fisher Scientific Inc.
    • 15.3.20. PierianDx, Inc.
    • 15.3.21. CRISPR Therapeutics AG
    • 15.3.22. bluebird bio, Inc.
    • 15.3.23. Vertex Pharmaceuticals Incorporated

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. PERSONALIZED MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. PERSONALIZED MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. PERSONALIZED MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. PERSONALIZED MEDICINE MARKET: RESEARCHAI
  • FIGURE 24. PERSONALIZED MEDICINE MARKET: RESEARCHSTATISTICS
  • FIGURE 25. PERSONALIZED MEDICINE MARKET: RESEARCHCONTACTS
  • FIGURE 26. PERSONALIZED MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. PERSONALIZED MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 273. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 275. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 278. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 279. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 281. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 285. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 287. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 289. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 291. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 293. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 298. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 299. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 301. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 303. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 305. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 307. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 309. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 311. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 313. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. RUSSIA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 315. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 319. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 321. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 323. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 325. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
  • TABLE 327. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 328. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 329. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 331. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 333. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ITALY PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 335. SPAIN PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. SPAIN PERS